Please ensure Javascript is enabled for purposes of website accessibility

Moderna Reports Excellent Results From Coronavirus Vaccine Booster Trial

By Eric Volkman - May 5, 2021 at 8:05PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Two types of booster proved efficacious against a pair of more threatening coronavirus variants.

In a fresh shot of good news in the global battle against the coronavirus pandemic, Moderna (MRNA -2.60%) Wednesday reported highly encouraging preliminary results from a booster vaccine study.

The phase 2 study measured the efficacy of booster shots of the company's mRNA-1273 coronavirus vaccine. Two boosters were administered for the trial, one containing the original mRNA-1273, and another (mRNA-1273.351) specifically designed to combat the apparently more threatening South African variant of the coronavirus. In both cases, the boosters increased the body's production of neutralizing antibodies.

Also, they did so not only against the South African variant but another worrying one, the so-called Brazil variant.

The boosters were generally well tolerated, Moderna said, with most side effects being mild or moderate.

A man receiving a vaccination.

Image source: Getty Images.

They were administered to patients roughly six to eight months after the study's participants received their second shot of the two-jab mRNA-1273. The responses were measured 15 days after the booster.

"We are encouraged by these new data, which reinforce our confidence that our booster strategy should be protective against these newly detected variants." Moderna quoted its CEO Stephane Bancel as saying.

In the study, the company is also testing a multivalent booster, mRNA-1273.211, which is a combination of the other two boosters. The evaluation of this one is ongoing; Moderna said data is expected shortly.

The positive results of the trial Wednesday were overshadowed, however, by news that the Biden administration supports removing intellectual property protection from current coronavirus vaccines -- which of course includes mRNA-1273. If enacted, that could, of course, drastically reduce Moderna's revenue from its jab.

That's a key reason why Moderna stock fell by nearly 6.2% Wednesday, despite the happy news about the boosters. The S&P 500 index, meanwhile, effectively traded sideways.

 

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$146.10 (-2.60%) $-3.90

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.